Academic Journal
Q1Molecular Therapy Oncology
About Molecular Therapy Oncology
Molecular Therapy Oncology is a scholarly journal published by Cell Press. SCImago 2025 lists it in Q1, with an SJR of 1.79 and H-index of 57.
Coverage: 2024-2026. Research categories: Cancer Research (Q1); Molecular Medicine (Q1); Oncology (Q1); Pharmacology (medical) (Q1).
Open-access policies and author information
Reported in the official DOAJ public CSV snapshot (2026-09-01), downloaded 2026-10-03. Record updated 2026-04-27. This snapshot does not establish today’s listing status or fee quotation.
Publisher policy links recorded by DOAJ
- Aims and scope ↗
- Editorial board ↗
- Instructions for authors ↗
- Peer-review policy ↗
- Publication fees ↗
- Fee waivers ↗
- Licence terms ↗
- Copyright policy ↗
- Preservation policy ↗
Source: DOAJ journal record. Journal metadata is distributed by DOAJ under CC0. Confirm current fees, tax, eligibility and waiver terms with the publisher.
Source-backed journal facts
Topics in published research
CAR-T cell therapy research; Virus-based gene therapy research; Immunotherapy and Immune Responses; Immune Cell Function and Interaction; Cancer Research and Treatments; Cancer Immunotherapy and Biomarkers.
OpenAlex classifies topics from published works. These topics are not the publisher’s official aims and scope.
Source: OpenAlex source record. Retrieved 2026-10-03. Source record updated 2026-10-02. OpenAlex metrics are different from SCImago metrics and the Clarivate Journal Impact Factor.
Journal Metrics
Quartile, SJR and the listed SCImago H-index use the 2025 imported SCImago dataset. A quartile may vary by subject category. Values without a source or reporting year are unverified historical entries. Verify the current Journal Impact Factor with Clarivate or the publisher before using it.
Aims & Scope
The publisher’s official aims and scope have not yet been verified for this profile. Use the journal website to check subject fit and accepted article types before submitting.
Recent Research Articles
Latest publications matched automatically by ISSN.
Additive effect of Ruta graveolens bioactive phytoconstituents and cisplatin through PKC/MEK/ERK pathway in glioblastoma
Grazia Romano, Valentina Morgera, Antonio Pezone, Samantha Messina et al.
2026-12 · DOI: 10.1016/j.omton.2026.201350Preclinical evaluation of triple-mutated oncolytic herpes virus expressing fusion-type interleukin 12 for malignant melanoma
Miwako Iwai, Akiko Higuchi Nonaka, Minoru Tanaka, Hiroshi Fukuhara et al.
2026-12 · DOI: 10.1016/j.omton.2026.201334Engineering “off-the-shelf” TCR-T cells: A transient mRNA platform for balanced alloreactivity and functionality
Shan He, Yirong Dai, Qi Chen, Adeline Chia et al.
2026-12 · DOI: 10.1016/j.omton.2026.201335Turning immune checkpoint inhibitors into synthetic switches for engineered T cells
Yan-Ruide Li
2026-12 · DOI: 10.1016/j.omton.2026.201346FOXM1 drives cisplatin resistance in ovarian cancer through STIM1-mediated SOCE and STAT1 activation
Tzu-Chien Lin, Meng-Ru Hsieh, Hieu Dac Hanh Nguyen, Sarinporn Visitsattapongse et al.
2026-12 · DOI: 10.1016/j.omton.2026.201347Targeting the tumor, harboring the host: IL-7 receptor-targeted CARs to treat T-ALL
Valeriya Kuznetsova, Rishi K. Kothuru, Prasad S. Adusumilli, Alfredo Amador-Molina et al.
2026-12 · DOI: 10.1016/j.omton.2026.201345VIDA: A programmable gasdermin-mediated strategy to broaden mRNA therapeutics
Yi-Jiao Huang, Cheng-Feng Qin
2026-12 · DOI: 10.1016/j.omton.2026.201344An engineered PD-1 receptor-based CAR that binds anti-PD-1 antibodies but not PD-L1 to enhance T-cell functionality
Jordy Schaukens, Lorenzo Franceschini, Latoya Stevens, Fien Meeus et al.
2026-10 · DOI: 10.1016/j.omton.2026.201289CAR design equips diverse immune cells with unique antigen-specific activation identities
Ayano Sugiyama-Finnis, Takaharu Kimura, Kiyoko Izawa, Yuko Kawano et al.
2026-09 · DOI: 10.1016/j.omton.2026.201312CAR T cells against the B cell receptor to precisely eliminate pathogenic B cells
Audrey C. Bochi-Layec, Ivan J. Cohen, Jean Lemoine, Marco Ruella et al.
2026-09 · DOI: 10.1016/j.omton.2026.201297Unmasking Wnt-driven HCC: Inhibiting SMYD2 to overcome immune resistance
Xiupeng Chen, Allison M. Keeler, Joae Qiong Wu
2026-09 · DOI: 10.1016/j.omton.2026.201298Circulating miRNAs for glioblastoma monitoring: from biofluid to clinical decision
Arthur Leclerc, Evelyne Emery, Guénaëlle Levallet
2026-09 · DOI: 10.1016/j.omton.2026.201308Widening the therapeutic window: How tumor irradiation harnesses dendritic cells to locally amplify CAR T cells in solid tumor
Sophia Navarre, Jalal Ahmed
2026-09 · DOI: 10.1016/j.omton.2026.201317Synergistic cell-cycle repression by HDAC/EZH2 co-targeting in H3K27-altered diffuse midline glioma
Zili Zhen, Qiang Gao, Yong Ai, Zhihong Qian et al.
2026-09 · DOI: 10.1016/j.omton.2026.201306Development of chimeric antigen receptors targeting the γδ T cell receptor
Lauren C. Cutmore, Norris Lam, Christina Amatya, Katherine A. Weissler et al.
2026-09 · DOI: 10.1016/j.omton.2026.201260Intraperitoneal delivery of the oncolytic virus CF17 improves tumor immunogenicity and survival in gastric cancer peritoneal metastasis
Zhifang Zhang, Annie Yang, Anthony K. Park, Shyambabu Chaurasiya et al.
2026-09 · DOI: 10.1016/j.omton.2026.201266A novel combination approach targeting P300 and DNA-PK exploits epigenetic dependencies in acute myeloid leukemia
Srinivas Vinod Saladi, Swati Garg, Ellen L. Weisberg, Abigail E. Case et al.
2026-09 · DOI: 10.1016/j.omton.2026.201262Engineered indoleamine 2,3-dioxygenase variant: Oxidative activation of prodrug indole-3-acetic acid against cancer cells for targeted therapy
Liru Liu, Wanfang Li, Sheng Ye
2026-09 · DOI: 10.1016/j.omton.2026.201310Intramuscular plasmid DNA electroporation sequesters neoantigen-specific CD8+ T cells in treated muscle and limits tumor infiltration
Andrea Bianchi, Mauro Esposito, Tiziano Giacomelli, Ilaria Esposito et al.
2026-09 · DOI: 10.1016/j.omton.2026.201248Epitope Selection Overcomes Antigen Shedding to Enable Effective CAR-M Therapy in Solid Tumors
Wenlong Liu, Xiufen Liu, Seraphim Kozlov, Qi Zhou et al.
2026-09 · DOI: 10.1016/j.omton.2026.201354Reviews
Community Reviews
Version History
September 25, 2026 at 7:13 am
September 25, 2026